Elicio Therapeutics (ELTX) Current Leases (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Current Leases for 7 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases rose 12.71% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (up 12.71% YoY), and the FY2025 full-year result was $1.0 million, up 12.21% from the prior year.
• Current Leases climbed to $1.1 million in Q2 2026 per ELTX's latest filing, from $1.0 million in the prior quarter.
• Across five years, Current Leases topped out at $1.1 million in Q2 2026 and bottomed at $227000.0 in Q1 2023.
• Historically, Current Leases has averaged $893277.8 across 5 years, with a median of $932000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Current Leases tumbled 75.27% in 2023, then surged 288.11% in 2024.
• Over 5 years, Current Leases stood at $692000.0 in 2022, then surged by 31.5% to $910000.0 in 2023, then decreased by 0.99% to $901000.0 in 2024, then climbed by 12.21% to $1.0 million in 2025, then grew by 6.13% to $1.1 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.1 million, $1.0 million, and $1.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.